Intellia Therapeutics, Inc. 8-K

What Happened
Intellia Therapeutics, Inc. (NTLA) announced its financial results and business updates for the quarter ended March 31, 2026 in a press release dated May 11, 2026. The company furnished the full press release as Exhibit 99.1 to this Current Report on Form 8‑K. The report was signed by John M. Leonard, Chief Executive Officer and President.

Key Details

• Filing date: May 11, 2026 (Form 8‑K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Exhibit furnished: 99.1 — press release dated May 11, 2026 (and Inline XBRL cover page as Exhibit 104).
• Signature: John M. Leonard, CEO and President, authorized the filing.

Why It Matters
This 8‑K notifies investors that Intellia has reported its quarterly results (earnings/revenue and business update) for Q1 2026; the press release will contain the specific financial figures, program milestones, and any guidance or business developments that could affect the stock. Retail investors should read the furnished press release and any follow‑up SEC filings (for example the quarterly 10‑Q) to see revenue, net loss/profit, cash position, clinical or partnership updates, and management commentary before making investment decisions.